CancerIQ, a platform powering early cancer detection and prevention across broad patient populations, announced it closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.

McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ's Series A lead investor, HealthX Ventures, also participated in the Series B round.